FDA/CDC

FDA warns of serious side effect of AML treatment


 

Pages

Recommended Reading

Venetoclax gets accelerated approval in older AML patients
MDedge Hematology and Oncology
FDA approves glasdegib for AML
MDedge Hematology and Oncology
FDA approves gilteritinib for AML with FLT3 mutation
MDedge Hematology and Oncology
Your guide to ASH 2018: Abstracts to watch
MDedge Hematology and Oncology
Serious side effect of AML treatment going unnoticed, FDA warns
MDedge Hematology and Oncology
FDA approves gilteritinib for relapsed/refractory AML
MDedge Hematology and Oncology
FDA grants priority review to quizartinib
MDedge Hematology and Oncology
FDA approves venetoclax for AML
MDedge Hematology and Oncology
FDA approves glasdegib for AML
MDedge Hematology and Oncology
FDA approves generic drugs for APL
MDedge Hematology and Oncology